Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) (GLIDE)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03091933 |
|
Recruitment Status : Unknown
Verified December 2017 by Ciusss de L'Est de l'Île de Montréal.
Recruitment status was: Recruiting
First Posted : March 27, 2017
Last Update Posted : December 6, 2017
|
Sponsor:
Ciusss de L'Est de l'Île de Montréal
Information provided by (Responsible Party):
Ciusss de L'Est de l'Île de Montréal
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study will evaluate the safety of infusing an anti-MiHA T cell line in patients suffering from an hematologic malignancy that has relapsed following hematopoietic stem cell transplantation from a matched donor.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Hematologic Cancer Relapse Leukemia Relapsed Adult ALL Relapsed Adult AML Relapsed CLL Relapsed Non Hodgkin Lymphoma Relapsed Hodgkin's Lymphoma Relapsed Myelodysplastic Syndromes Relapsed Multiple Myeloma | Biological: GLIDE | Phase 1 Phase 2 |
The GLIDE-201/44 trial primarily aims to test the safety of anti-MiHA T cell line in patients suffering from an hematologic malignancy that has relapsed following hematopoietic stem cell transplantation from a matched donor. The anti-MiHA T cell lines are derived from the matched donor for the patient, the original donor for a given patient. Both the patient and the matched donor will undergo screening to determine the expression of targetable MiHAs. Upon identification of the target MiHAs, donor cells will be collected through apheresis and primed against the selected MiHA. In this setting, the GLIDE 201/44 product will be cryopreserved, thawed and administered as a single infusion at a target dose of 4x10E+07 viable T cells/m2 (range of dose is 0.4 4x10E+07 viable T cells/m2). A second infusion can be offered to the patients after an observation period of 42 days upon clinical evaluation by the treating physician. In the absence of secondary adverse events following the initial infusion, a second infusion of the GLIDE 201/44 product could be administered at a dose level up to 3-5 fold the original dose.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 20 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Intervention Model Description: | exploratory, open-label |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Exploratory, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Anti-minor Histocompatibility Complex (MiHA) Donor T-lymphocytes Expanded ex Vivo, in Patients With a Hematologic Malignancy, With Molecular or Clinical Relapse After Hematopoietic Stem Cell Transplantation From a Matched Donor |
| Actual Study Start Date : | February 6, 2017 |
| Estimated Primary Completion Date : | March 31, 2018 |
| Estimated Study Completion Date : | March 31, 2019 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Experimental: GLIDE
GLIDE single infusion at a target dose of 4x107 viable T-cells/m2
|
Biological: GLIDE
Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line |
Primary Outcome Measures :
- Non-hematologic toxicity related to GLIDE post injection [ Time Frame: 6 months ]No death or other toxic events directly related to GLIDE injection
Secondary Outcome Measures :
- Response of hematologic malignancy (acute leukemia (ALL, AML, biphenotypic), CLL, HL, NHL, MM or MDS) post-injection [ Time Frame: up to 12 months ]Disease progression following GLIDE injection
- Incidence and severity of acute and chronic graft versus host disease (GvHD) [ Time Frame: up to 12 months ]Progression (if any) or induction of GvHD
- Persistence of GLIDE in the host and homing to peripheral blood, bone marrow and other tissues [ Time Frame: up to 12 months ]Monitoring of GLIDE product persistence in host
- Non-Relapse mortality (NRM) [ Time Frame: up to 12 months ]Time to deaths without relapse/recurrence
- Relapse-incidence (RI) [ Time Frame: up to 12 months ]Time to relapse
- Overall survival (OS) [ Time Frame: up to 12 months ]Time to death, irrespective of the cause
- Progression-free survival (PFS) [ Time Frame: up to 12 months ]It is time to any of the following: OS, RI, NRM, Time to relapse, Relapse free survival
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Prior allogeneic HLA-matched stem cell transplantation
- Any of the following hematologic malignancies:
- Acute myeloid leukemia (AML)
- Acute lymphoblastic leukemia (ALL)
- Biphenotypic leukemia
- Chronic lymphoblastic leukemia (CLL)
- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma (NHL)
- Multiple Myeloma (MM)
- Myelodysplastic syndrome (MDS)
- Presence of HLA2:01 and / or HLA44:02 and / or HLA-B*44:03, HLA-A*01:01; HLA-A*03:01; HLA-A*11:01;HLA A*24:02; HLA-A*29:02; HLA-A*32:01; HLA-B*07:02; HLA-B*08:01; HLA B*13:02; HLA-B*14:02; HLA-B*15:01; HLA-B*18:01; HLA-B*27:05; HLA B*35:01; HLA-B*40:01; or HLA-B*57:01
- At least 6 months after allogeneic hematopoietic stem cell transplantation
- Presence of detectable malignant disease post-transplantation in the form of molecular, cytogenetic or hematologic relapse of the malignant disorder.
- Eligible to receive cytoreductive chemotherapy
- Original stem cell donor available for leukocyte donation.
- ECOG performance status ≤2.
- Ability to provide written consent.
- Accessible for treatment and follow up.
- Presence of a targetable MiHA based on exome sequencing of the patient and donor
Exclusion Criteria:
- Active acute GVHD > grade I
- Prior grade III-IV acute GVHD within the last year
- Uncontrolled chronic GVHD
- Prior administration of donor lymphocyte infusion (DLI)
- Use of T-cell depleting antibodies in the previous 30 days
- Treatment with immune suppressors (oral or parenteral steroids corresponding to a dose of prednisone greater than 7.5 mg/day, calcineurine inhibitors, rapamycin, mycophenolate mofetil, etc) during the last 30 days.
- Uncontrolled active infection
- Uncontrolled central nervous system involvement by leukemia cells (blasts).
- AST or ALT > 2.5 x ULN (CTCAE grade 2)
- Bilirubin > 1.5 x ULN (CTCAE grade 2)
- Creatinine clearance < 50 mL/min
- Positive test for human immunodeficiency virus (HIV)
- Positive pregnancy test (women of childbearing age only)
- Lactating women: the safety of this therapy on breast milk is not known.
- Estimated probability of surviving less than 3 months
- Known allergy to any of the components of GLIDE (e.g., dimethyl sulfoxide)
- Intercurrent illness or medical condition precluding safe administration of the planned protocol treatment or required follow-up.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03091933
Contacts
| Contact: Jean-Guy Némorin, PhD | (514) 252-3400 ext 6247 | jgnemorin@centrec3i.com | |
| Contact: Stéphanie Thiant, PhD | (514) 252-3400 ext 4681 | sthiant.hmr@ssss.gouv.qc.ca |
Locations
| Canada, Quebec | |
| CIUSSS d l'Est-de-l'Île-de-Montréal | Recruiting |
| Montreal, Quebec, Canada, H1T 2M4 | |
| Contact: Jean-Guy Némorin, PhD 514-252-3400 ext 6247 jgnemorin@centrec3i.com | |
| Contact: Stéphanie Thiant, PhD 214-252-3400 ext 4681 sthiant.hmr@ssss.gouv.qc.ca | |
| Principal Investigator: Denis-Claude Roy, MD PhD | |
| Sub-Investigator: Jean-Sébastien Delisle, MD PhD | |
| Sub-Investigator: Silvy Lachance, MD | |
Sponsors and Collaborators
Ciusss de L'Est de l'Île de Montréal
Investigators
| Principal Investigator: | Denis-Claude Roy, MD PhD | CIUSSS d l'Est-de-l'Île-de-Montréal | |
| Principal Investigator: | Jean-Sébastien Delisle, MD PhD | CIUSSS d l'Est-de-l'Île-de-Montréal | |
| Principal Investigator: | Silvy Lachance, MD | CIUSSS d l'Est-de-l'Île-de-Montréal |
| Responsible Party: | Ciusss de L'Est de l'Île de Montréal |
| ClinicalTrials.gov Identifier: | NCT03091933 |
| Other Study ID Numbers: |
CR-MIHA-001 |
| First Posted: | March 27, 2017 Key Record Dates |
| Last Update Posted: | December 6, 2017 |
| Last Verified: | December 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Plan Description: | De-identified individual participant data for all primary and secondary outcome measures will be made available within 6 months of study end |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Ciusss de L'Est de l'Île de Montréal:
|
allogeneic hematopoietic stem cell transplantation relapsed hematopoietic malignancy HLA matched donor minor histocompatibilty antigen (MiHA) |
Additional relevant MeSH terms:
|
Lymphoma Multiple Myeloma Neoplasms Hematologic Neoplasms Myelodysplastic Syndromes Recurrence Neoplasms by Histologic Type Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Neoplasms, Plasma Cell |
Hemostatic Disorders Vascular Diseases Cardiovascular Diseases Paraproteinemias Blood Protein Disorders Hematologic Diseases Hemorrhagic Disorders Bone Marrow Diseases Disease Attributes Pathologic Processes Neoplasms by Site |